171 related articles for article (PubMed ID: 34331551)
1. Pharmacodynamic effects of indobufen compared with aspirin in patients with coronary atherosclerosis.
Yang M; Ye Z; Mei L; Ullah I; Tan C; Wang G; Gu Q; Lu Y; Abdus S; Shi L; Gong X; Bai J; Eikelboom JW; Li C
Eur J Clin Pharmacol; 2021 Dec; 77(12):1815-1823. PubMed ID: 34331551
[TBL] [Abstract][Full Text] [Related]
2. Comparison of aspirin and indobufen in healthy volunteers.
Lee JY; Sung KC; Choi HI
Platelets; 2016; 27(2):105-9. PubMed ID: 26083594
[TBL] [Abstract][Full Text] [Related]
3. Clopidogrel plus indobufen in acute coronary syndrome patients with hypersensitivity to aspirin undergoing percutaneous coronary intervention.
Barillà F; Pulcinelli FM; Mangieri E; Torromeo C; Tanzilli G; Dominici T; Pellicano M; Paravati V; Acconcia MC; Gaudio C
Platelets; 2013; 24(3):183-8. PubMed ID: 22646157
[TBL] [Abstract][Full Text] [Related]
4. Indobufen: an updated review of its use in the management of atherothrombosis.
Bhana N; McClellan KJ
Drugs Aging; 2001; 18(5):369-88. PubMed ID: 11392445
[TBL] [Abstract][Full Text] [Related]
5. Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina.
Cipollone F; Patrignani P; Greco A; Panara MR; Padovano R; Cuccurullo F; Patrono C; Rebuzzi AG; Liuzzo G; Quaranta G; Maseri A
Circulation; 1997 Aug; 96(4):1109-16. PubMed ID: 9286937
[TBL] [Abstract][Full Text] [Related]
6. Effect of indobufen vs. aspirin on platelet accumulation in patients with stable coronary heart disease after percutaneous coronary intervention: An open-label crossover study.
Shi QP; Luo XY; Zhang B; Wang XG; Zhao J; Xie QF; Liu JH; Liu YK; Jiang J; Zheng B
Front Pharmacol; 2022; 13():950719. PubMed ID: 36052139
[No Abstract] [Full Text] [Related]
7. Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease.
Capodanno D; Patel A; Dharmashankar K; Ferreiro JL; Ueno M; Kodali M; Tomasello SD; Capranzano P; Seecheran N; Darlington A; Tello-Montoliu A; Desai B; Bass TA; Angiolillo DJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):180-7. PubMed ID: 21386092
[TBL] [Abstract][Full Text] [Related]
8. A prostacyclin-sparing effect of indobufen vs. aspirin.
De Caterina R; Giannessi D; Bernini W; Lazzerini G; Lavezzari M; Stragliotto E; Biagi G; Coccheri S
Thromb Haemost; 1996 Mar; 75(3):510-4. PubMed ID: 8701417
[TBL] [Abstract][Full Text] [Related]
9. In vitro and ex vivo effects of indobufen on human platelet aggregation, the release reaction and thromboxane B2 production.
Cattaneo M; Bevilacqua C; Lecchi A; Mannucci PM
Haemostasis; 1987; 17(5):293-300. PubMed ID: 3666587
[TBL] [Abstract][Full Text] [Related]
10. In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia.
Davi G; Alessandrini P; Mezzetti A; Minotti G; Bucciarelli T; Costantini F; Cipollone F; Bon GB; Ciabattoni G; Patrono C
Arterioscler Thromb Vasc Biol; 1997 Nov; 17(11):3230-5. PubMed ID: 9409316
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus.
Davì G; Patrono C; Catalano I; Custro N; Giammarresi C; Ganci A; Cosentino F; Notarbartolo A
Arterioscler Thromb; 1993 Sep; 13(9):1346-9. PubMed ID: 8364018
[TBL] [Abstract][Full Text] [Related]
12. Defining platelet response to acetylsalicylic acid: the relation between inhibition of serum thromboxane B
Gurbel PA; Bliden KP; Tantry US
J Thromb Thrombolysis; 2021 Feb; 51(2):260-264. PubMed ID: 33170486
[TBL] [Abstract][Full Text] [Related]
13. The d-enantiomer form of indobufen totally accounts for the anti-cyclooxygenase and antiplatelet activity ex vivo and for the increase in bleeding time by indobufen in man.
De Caterina R; Sicari R; Yan A; Bernini W; Giannessi D; Lazzerini G; Efthymiopoulos C; Strolin-Benedetti M
Thromb Haemost; 1992 Feb; 67(2):258-63. PubMed ID: 1621247
[TBL] [Abstract][Full Text] [Related]
14. Once versus twice daily aspirin after coronary bypass surgery: a randomized trial.
Paikin JS; Hirsh J; Ginsberg JS; Weitz JI; Chan NC; Whitlock RP; Pare G; Eikelboom JW
J Thromb Haemost; 2017 May; 15(5):889-896. PubMed ID: 28267249
[TBL] [Abstract][Full Text] [Related]
15. The (+)-enantiomer is responsible for the antiplatelet and anti-inflammatory activity of (+/-)-indobufen.
Cerletti C; Manarini S; Colombo M; Tavani A
J Pharm Pharmacol; 1990 Dec; 42(12):885-7. PubMed ID: 1983157
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial to assess the pharmacodynamics and pharmacokinetics of a single dose of an extended-release aspirin formulation.
Patrick J; Dillaha L; Armas D; Sessa WC
Postgrad Med; 2015 Aug; 127(6):573-80. PubMed ID: 25998572
[TBL] [Abstract][Full Text] [Related]
17. Indobufen is a potent inhibitor of whole blood aggregation in patients with a high atherosclerotic risk.
Mannucci L; Maderna P; Colli S; Lavezzari M; Sirtori CR; Tremoli E
Thromb Res; 1987 Nov; 48(4):417-26. PubMed ID: 3445229
[TBL] [Abstract][Full Text] [Related]
18. Multiple daily doses of acetyl-salicylic acid (ASA) overcome reduced platelet response to once-daily ASA after coronary artery bypass graft surgery: a pilot randomized controlled trial.
Paikin JS; Hirsh J; Ginsberg JS; Weitz JI; Chan NC; Whitlock RP; Pare G; Johnston M; Eikelboom JW
J Thromb Haemost; 2015 Mar; 13(3):448-56. PubMed ID: 25546465
[TBL] [Abstract][Full Text] [Related]
19. Effect of polymorphism and type II diabetes on aspirin resistance in patients with unstable coronary artery disease.
Gao F; Wang ZX; Men JL; Ren J; Wei MX
Chin Med J (Engl); 2011 Jun; 124(11):1731-4. PubMed ID: 21740787
[TBL] [Abstract][Full Text] [Related]
20. Optical platelet aggregation versus thromboxane metabolites in healthy individuals and patients with stable coronary artery disease after low-dose aspirin administration.
Hedegaard SS; Hvas AM; Grove EL; Refsgaard J; Rocca B; Daví G; Kristensen SD
Thromb Res; 2009 May; 124(1):96-100. PubMed ID: 19215971
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
